BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 16275936)

  • 21. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
    Fermand JP; Ravaud P; Chevret S; Divine M; Leblond V; Belanger C; Macro M; Pertuiset E; Dreyfus F; Mariette X; Boccacio C; Brouet JC
    Blood; 1998 Nov; 92(9):3131-6. PubMed ID: 9787148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
    Boccadoro M; Tarella C; Palumbo A; Argentino C; Triolo S; Dominietto A; Callea V; Lauta VM; Molica S; Musto P; Marmont F; Gianni AM; Pileri A
    Haematologica; 1999 Oct; 84(10):905-10. PubMed ID: 10509038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
    Attal M; Harousseau JL; Stoppa AM; Sotto JJ; Fuzibet JG; Rossi JF; Casassus P; Maisonneuve H; Facon T; Ifrah N; Payen C; Bataille R
    N Engl J Med; 1996 Jul; 335(2):91-7. PubMed ID: 8649495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma.
    Einsele H; Bamberg M; Budach W; Schmidberger H; Hess CF; Wörmann B; Meisner C; Straka C; Hebart H; Trümper L; Kröger N; Zander AR; Hegewisch-Becker S; Hossfeld DK; Schmidt H; Müller P; Schlimok G; Hertenstein B; Peest D; Metzner B; Frickhofen N; Kanz L; Bensinger WI
    Bone Marrow Transplant; 2003 Sep; 32(6):593-9. PubMed ID: 12953132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.
    Moreau P; Misbahi R; Milpied N; Morineau N; Mahé B; Vigier M; Rapp MJ; Bataille R; Harousseau JL
    Leukemia; 2002 Sep; 16(9):1838-43. PubMed ID: 12200701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission.
    Nadal E; Giné E; Bladé J; Esteve J; Rosiñol L; Fernández-Avilés F; Marin P; Martinez C; Rovira M; Urbano-Ispizua A; Carreras E; Montserrat E
    Bone Marrow Transplant; 2004 Jan; 33(1):61-4. PubMed ID: 14704657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
    J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High dose chemotherapy and autologous stem cell transplantation in patients with multiple myeloma: the experience of a single haematological unit.
    Papanikolaou X; Maltezas D; Repousis P; Athanassopoulos A; Alexia S; Megalakaki K; Kotsopoulou M; Mitsouli-Mentzikof C
    J BUON; 2008; 13(2):193-7. PubMed ID: 18555464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution.
    Bladé J; Esteve J; Rives S; Martínez C; Rovira M; Urbano-Ispizua A; Marín P; Carreras E; Montserrat E
    Bone Marrow Transplant; 2000 Oct; 26(8):845-9. PubMed ID: 11081383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
    Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
    Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R
    Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
    Benson DM; Elder PJ; Lin TS; Blum W; Penza S; Avalos B; Copelan E; Farag SS
    Leuk Res; 2007 Aug; 31(8):1069-75. PubMed ID: 17070906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
    Vitolo U; Liberati AM; Cabras MG; Federico M; Angelucci E; Baldini L; Boccomini C; Brugiatelli M; Calvi R; Ciccone G; Genua A; Deliliers GL; Levis A; Parvis G; Pavone E; Salvi F; Sborgia M; Gallo E;
    Haematologica; 2005 Jun; 90(6):793-801. PubMed ID: 15951292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
    J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Oberlin O; Rey A; Desfachelles AS; Philip T; Plantaz D; Schmitt C; Plouvier E; Lejars O; Rubie H; Terrier P; Michon J;
    J Clin Oncol; 2006 Aug; 24(24):3997-4002. PubMed ID: 16921053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy].
    Shimokawa T; Kajiguchi T; Saito M; Kojima Y; Takeyama H
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):251-4. PubMed ID: 12610874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.